Form 4: Enzo Biochem CEO Kara Cannon Reports Stock Transaction Following RSU Vesting
SEC Form 4
Kara Cannon, CEO of Enzo Biochem, reports the withholding of shares to cover tax obligations after the vesting of restricted stock units.
Summary
- On July 24, 2024, Kara Cannon, the CEO of Enzo Biochem, reported a transaction involving the company's common stock.
- 70,885 shares were withheld by Enzo Biochem to satisfy tax withholding requirements related to the vesting of 215,210 Restricted Stock Units (RSUs) that vested on July 24, 2024.
- The price per share for the transaction was $1.17.
- Following the transaction, Cannon directly owns 380,412 shares and indirectly owns 45,065 shares through a 401k.
Sentiment
Score: 5
Explanation: This is a neutral event related to executive compensation and tax obligations. It doesn't indicate a positive or negative outlook for the company.
Industry Context
This is a routine transaction related to executive compensation and tax obligations. It is common for companies to withhold shares to cover taxes when RSUs vest.
Key Dates
| Date | Description |
|---|---|
| 08/31/2023 | Reporting Person was granted 215,210 Restricted Stock Units (RSUs). |
| 07/24/2024 | Date of Earliest Transaction: 70,885 shares of common stock were withheld to satisfy tax withholding requirements in connection with the vesting of RSUs. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.